Nuo Therapeutics, Inc. (AURX) stock
AURXOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$1.26−0.04 (-3.08%)
Close on Oct 19, 2026Market cap $60.99MP/E –Yield –
Nuo Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Nuo Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -38.7%. For fiscal 2025 it was -75.8%, against -170.2% the year before. The highest annual figure on record is -48.4% in fiscal 2011.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -75.8% | +94.4 |
| FY2024 | Dec 31, 2024 | -170.2% | +351.0 |
| FY2023 | Dec 31, 2023 | -521.2% | +2304.4 |
| FY2022 | Dec 31, 2022 | -2825.6% | −2008.2 |
| FY2019 | Dec 31, 2019 | -817.4% | −704.9 |
| FY2018 | Dec 31, 2018 | -112.5% | +1964.9 |
| FY2017 | Dec 31, 2017 | -2077.4% | −1618.6 |
| FY2015 | Dec 31, 2015 | -458.8% | −215.5 |
| FY2014 | Dec 31, 2014 | -243.3% | −68.3 |
| FY2013 | Dec 31, 2013 | -175.0% | +12.4 |
| FY2012 | Dec 31, 2012 | -187.4% | −139.0 |
| FY2011 | Dec 31, 2011 | -48.4% | +125.9 |
| FY2010 | Dec 31, 2010 | -174.3% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -15.7% | +77.1 |
| Q1 FY2026 | Mar 31, 2026 | -47.5% | +106.5 |
| Q4 FY2025 | Dec 31, 2025 | -52.7% | +73.0 |
| Q3 FY2025 | Sep 30, 2025 | -52.1% | +103.7 |
| Q2 FY2025 | Jun 30, 2025 | -92.8% | +55.3 |
| Q1 FY2025 | Mar 31, 2025 | -154.0% | +148.1 |
| Q4 FY2024 | Dec 31, 2024 | -125.8% | +205.7 |
| Q3 FY2024 | Sep 30, 2024 | -155.9% | +184.6 |
| Q2 FY2024 | Jun 30, 2024 | -148.1% | +589.8 |
| Q1 FY2024 | Mar 31, 2024 | -302.2% | +1098.4 |
| Q4 FY2023 | Dec 31, 2023 | -331.5% | +965.1 |
| Q3 FY2023 | Sep 30, 2023 | -340.4% | +2045.9 |
| Q2 FY2023 | Jun 30, 2023 | -737.8% | −1919.9 |
| Q1 FY2023 | Mar 31, 2023 | -1400.6% | −1240.6 |
| Q4 FY2022 | Dec 31, 2022 | -1296.6% | −209.2 |
| Q3 FY2022 | Sep 30, 2022 | -2386.4% | −653.2 |
| Q4 FY2019 | Dec 31, 2019 | 1182.1% | +1136.7 |
| Q3 FY2019 | Sep 30, 2019 | -160.0% | +89.7 |
| Q2 FY2019 | Jun 30, 2019 | -1087.5% | −660.8 |
| Q1 FY2019 | Mar 31, 2019 | -1733.2% | −1314.1 |
| Q4 FY2018 | Dec 31, 2018 | 45.4% | +4094.4 |
| Q3 FY2018 | Sep 30, 2018 | -249.7% | +599.2 |
| Q2 FY2018 | Jun 30, 2018 | -426.7% | +1647.6 |
| Q1 FY2018 | Mar 31, 2018 | -419.1% | +560.8 |
| Q4 FY2017 | Dec 31, 2017 | -4049.1% | −2964.8 |
| Q3 FY2017 | Sep 30, 2017 | -848.9% | – |
| Q2 FY2017 | Jun 30, 2017 | -2074.3% | – |
| Q1 FY2017 | Mar 31, 2017 | -979.8% | – |
| Q3 FY2016 | Sep 30, 2016 | -1084.3% | – |
See a number that looks wrong?